Literature DB >> 23496233

Clinical implication of microrna for lung cancer.

Yang Wang1, Xinwei Zhang, Liang Liu, Hui Li, Jinpu Yu, Changli Wang, Xiubao Ren.   

Abstract

MicroRNAs (miRNAs) are a class of endogenous small noncoding regulatory RNAs, which are new regulators of gene expression. They interfere with multiple biological processes involved in tumorigenesis such as cell proliferation, cell cycle, apoptosis, angiogenesis, invasion, and metastasis. A large body of evidence shows that the aberrant expression of miRNAs in cancer patients provides numerous underlying merits as diagnostic, clinical pathological, prognostic markers, and as promising therapeutic targets of lung cancer, providing an insight into the clinical application for lung cancer. Here, we focus on specific miRNAs as biomarkers in lung cancer and briefly introduce the biological function and modification of miRNAs.

Entities:  

Keywords:  biomarker; diagnosis; lung cancer; miRNA; prognosis

Mesh:

Substances:

Year:  2013        PMID: 23496233     DOI: 10.1089/cbr.2012.1401

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  4 in total

1.  Decision tree-based classifiers for lung cancer diagnosis and subtyping using TCGA miRNA expression data.

Authors:  Masih Sherafatian; Fateme Arjmand
Journal:  Oncol Lett       Date:  2019-06-10       Impact factor: 2.967

2.  An integrated framework for the identification of potential miRNA-disease association based on novel negative samples extraction strategy.

Authors:  Chun-Chun Wang; Xing Chen; Jun Yin; Jia Qu
Journal:  RNA Biol       Date:  2019-01-28       Impact factor: 4.652

3.  miR-19a/b modulates lung cancer cells metastasis through suppression of MXD1 expression.

Authors:  Wenxia Hu; Pule Jin; Cuimin Ding; Wei Liu
Journal:  Oncol Lett       Date:  2016-07-19       Impact factor: 2.967

Review 4.  MicroRNAs in Vascular Eye Diseases.

Authors:  Chi-Hsiu Liu; Shuo Huang; William R Britton; Jing Chen
Journal:  Int J Mol Sci       Date:  2020-01-19       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.